Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


18.07.24 / Tradegate WKN: A2PEYJ / Name: Mereo Biopharma Group Ltd. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Mereo Biopharma Group Ltd. Stock

We can see a decrease in the price for Mereo Biopharma Group Ltd.. Compared to yesterday it has lost -€0.070 (-1.960%).
Currently there is a rather positive sentiment for Mereo Biopharma Group Ltd. with 4 Buy predictions and 0 Sell predictions.
With a target price of 5 € there is a positive potential of 40.85% for Mereo Biopharma Group Ltd. compared to the current price of 3.55 €.
So far the community has only identified positive things for Mereo Biopharma Group Ltd. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Mereo Biopharma Group Ltd. in the next few years

G***** c******* t* c**********
M***** P*******
S********** s********
C******** o* t** e**********
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Mereo Biopharma Group Ltd., a biopharmaceutical company, appears to have experienced significant financial fluctuations over the past few years. At first glance, it seems that the company has faced challenges in generating consistent revenues and maintaining a stable cash position. However, a closer examination of Mereo's financial statements may provide more insights into its financial strengths and weaknesses.

Improving Total Assets: Mereo Biopharma's total assets increased from £62.9 million in 2020 to £88 million in 2022, demonstrating growth in the company's overall resources.

Solid Cash Position: The company has maintained a relatively strong cash position over the past few years. As of 2022-12-31, Mereo Biopharma had £56.3 million in cash, which can help fuel its research activities and support ongoing operations.


Buy Mereo Biopharma Group Ltd.
Show more